Buscar
Congreso SOLACI
HomeCoronary diseaseChronic Ischemic cardiopathy

Chronic Ischemic cardiopathy

Ver Categoría

Antiplatelet

How to Discontinue Antiplatelet Therapy Prior Non-Cardiac Surgery

Both the indication and discontinuation of antiplatelet therapy to balance ischemic-bleeding risks has been left to physician...
solaci -
Ver más
Chronic Ischemic cardiopathy

[APT Medical Sponsored Clinical Case] Bilateral Distal Transradial Access for Chronic Total Occlusion Recanalization and Multivessel Coronary Disease Percutaneous Intervention

Introduction Chronic total occlusion (CTO) represents the most challenging setting for percutaneous coronary intervention (PCI) and multivessel coronary...
solaci -
Ver más
Chronic Ischemic cardiopathy

CT and Angiography Agreement in Patients from the ISCHEMIA Trial

Computed tomographic (CT) angiography showed a high degree of agreement with conventional angiography to detect significant coronary...
solaci -
Ver más
Chronic Ischemic cardiopathy

IVUS vs OCT to Guide PCI: Which Should We Choose?

Controlling stent expansion with optical coherence tomography (OCT) based on an external elastic membrane–based protocol for stent...
solaci -
Ver más
Chronic Ischemic cardiopathy

The Future of Prevention? Stenting Vulnerable Fractional FFR Negative Lesions

For many patients, the first symptom of heart disease is acute MI, or even sudden death.  Changes in...
solaci -
Ver más
Chronic Ischemic cardiopathy

Impact of FFR After Stenting: Useful or Mere Fun Fact?

Suboptimal fractional flow reserve (FFR) results after stenting only have a moderate impact on clinical hard points...
solaci -
Ver más
Antiplatelet

Short Therapy and Monotherapy, Plenty of Evidence

A short dual antiplatelet therapy (DAPT) of 1 to 3 months followed by P2Y12 inhibitor monotherapy after...
solaci -
Ver más
Chronic Ischemic cardiopathy

Medical Therapy Optimization Achieved Prior Clinical Trial

12 weeks prior the ORBITA randomization, medical therapy optimization of all antianginal medication was achieved.   Most importantly, optimization...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Noticias Institucionales

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad